Recbio Tech Stack

Vaccine developer with protein engineering and adjuvant platforms

Biotechnology Taizhou, Jiangsu 201–500 employees Founded 2012 Public Company

Recbio is a vaccine manufacturer building three core technology platforms: novel adjuvants, protein engineering, and immunological evaluation. The tech stack reveals a manufacturing-focused operation—SAP for enterprise resource planning, MES and SCADA for production control, and specialized bioanalytical tools (HPLC, HPLC-MS, ELISPOT, FlowJo) for candidate testing. Active projects span platform development, manufacturing automation, and regulatory compliance, with research roles dominating the hiring mix, signaling ongoing candidate advancement toward clinical trials.

Tech Stack 11 technologies

Core StackSAP MES BMS SCADA WinCC SDS-PAGE HPLC HPLC-MS ELISPOT GraphPad Prism FlowJo

What Recbio Is Building

◆Challenges

Meeting regulatory requirements
Expression system optimization
Platform capability building
Risk control
Technical problem resolution
Improving performance management system
Optimizing performance management methods
Solving implementation problems
Standardizing immunoanalysis methods
Establishing quality management system

▲Active Projects

Compliance procedure development
Information system construction
Antigen transient expression and stable cell line development
Expression system optimization
New vaccine delivery platform
Candidate vaccine in vitro and in vivo research
New factory automation system design
Fat/sat of automation system
Performance system build and launch
Performance training program

Hiring Activity

Minimal20 roles · 1 in 30d

Department

Research

Manufacturing

Engineering

Finance

Healthcare

Product

Seniority

Mid

Senior

Director

Intern

Junior

Manager

Company intelligence

Find more companies like Recbio by tech stack, pain points and active projects

Get started free

About Recbio

Recbio develops recombinant protein and viral vaccines across multiple indications, including HPV, COVID-19, shingles, influenza, and tuberculosis. Founded in 2012 and publicly listed on HKEX, the company operates from Taizhou, Jiangsu, with a team of 201–500 that includes core scientific staff with 20+ years of vaccine development experience. The organization balances research-driven candidate discovery with manufacturing scale-up, evidenced by concurrent projects in expression system optimization, factory automation, and quality management system deployment.

HeadquartersTaizhou, Jiangsu

Company Size201–500 employees

Founded2012

Hiring MarketsChina

Frequently Asked Questions

What manufacturing systems does Recbio use?

Recbio's production infrastructure includes SAP for ERP, MES for manufacturing execution, SCADA for process control, and WinCC for supervisory interface. Bioanalytical testing relies on HPLC, HPLC-MS, ELISPOT, and FlowJo for candidate characterization.

What vaccine candidates is Recbio developing?

The portfolio includes recombinant protein vaccines, HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, and adults TB vaccine candidates, backed by three proprietary platforms.